Design, synthesis and crystallization of a novel glucagon analog as a therapeutic agent
- PMID: 17620721
- PMCID: PMC2335127
- DOI: 10.1107/S1744309107028655
Design, synthesis and crystallization of a novel glucagon analog as a therapeutic agent
Abstract
Glucagon and glucagon-like peptide 1 (GLP-1) are drugs or drug candidates for the treatment of metabolic diseases such as diabetes and obesity. The native hormones have pharmacological deficiencies such as short half-life and poor solubility. A novel glucagon receptor agonist named glucagon-Cex has been designed, synthesized and crystallized. This peptide was highly soluble under physiological conditions and crystallized readily. The crystal diffracted X-rays to 2.2 A resolution and the diffraction was consistent with space group P23, with unit-cell parameters a = b = c = 48.20 A, alpha = beta = gamma = 90.0 degrees. The crystals were suitable for a full structural determination to reveal the conformational differences between glucagon-Cex and the native hormone.
Figures
Similar articles
-
Optimization of the native glucagon sequence for medicinal purposes.J Diabetes Sci Technol. 2010 Nov 1;4(6):1322-31. doi: 10.1177/193229681000400605. J Diabetes Sci Technol. 2010. PMID: 21129326 Free PMC article.
-
N-terminal His(7)-modification of glucagon-like peptide-1(7-36) amide generates dipeptidyl peptidase IV-stable analogues with potent antihyperglycaemic activity.J Endocrinol. 2004 Mar;180(3):379-88. doi: 10.1677/joe.0.1800379. J Endocrinol. 2004. PMID: 15012592
-
The multifaceted potential of glucagon-like peptide-1 as a therapeutic agent.Minerva Endocrinol. 2002 Jun;27(2):79-93. Minerva Endocrinol. 2002. PMID: 11961501 Review.
-
Proglucagon-derived peptides: mechanisms of action and therapeutic potential.Physiology (Bethesda). 2005 Oct;20:357-65. doi: 10.1152/physiol.00030.2005. Physiology (Bethesda). 2005. PMID: 16174875 Review.
-
NN-2211 Novo Nordisk.IDrugs. 2003 Mar;6(3):251-8. IDrugs. 2003. PMID: 12789615 Review.
Cited by
-
Optimization of the native glucagon sequence for medicinal purposes.J Diabetes Sci Technol. 2010 Nov 1;4(6):1322-31. doi: 10.1177/193229681000400605. J Diabetes Sci Technol. 2010. PMID: 21129326 Free PMC article.
-
Are peptide conjugates the golden therapy against obesity?J Endocrinol. 2018 Aug;238(2):R109-R119. doi: 10.1530/JOE-18-0264. Epub 2018 May 30. J Endocrinol. 2018. PMID: 29848610 Free PMC article. Review.
-
Structural transitions and interactions in the early stages of human glucagon amyloid fibrillation.Biophys J. 2015 Feb 17;108(4):937-948. doi: 10.1016/j.bpj.2015.01.004. Biophys J. 2015. PMID: 25692598 Free PMC article.
-
Novel use of glucagon in a closed-loop system for prevention of hypoglycemia in type 1 diabetes.Diabetes Care. 2010 Jun;33(6):1282-7. doi: 10.2337/dc09-2254. Epub 2010 Mar 23. Diabetes Care. 2010. PMID: 20332355 Free PMC article. Clinical Trial.
References
-
- Bolli, G. B. (1984). Diabetologia, 27, 485. - PubMed
-
- Estall, J. L. & Drucker, D. J. (2006). Curr. Pharm. Des.12, 1731–1750. - PubMed
-
- Fanelli, C. G., Porcellati, F., Rossetti, P. & Bolli, G. B. (2006). Nutr. Metab. Cardiovasc. Dis.16, Suppl. 1, S28–S34. - PubMed
-
- Fehse, F., Trautmann, M., Holst, J. J., Halseth, A. E., Nanayakkara, N., Nielsen, L. L., Fineman, M. S., Kim, D. D. & Nauck, M. A. (2005). J. Clin. Endocrinol. Metab.90, 5991–5997. - PubMed
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources